{"id":"amphotalide","rwe":[{"pmid":"14250531","year":"1964","title":"[STUDY OF THE ANTIBILHARZIC ACTION OF AMPHOTALIDE AS A FUNCTION OF THE DOSAGES EMPLOYED. RESULTS CONCERNING 25 CASES TREATED].","finding":"","journal":"Bulletin de la Societe de pathologie exotique et de ses filiales","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"amphothalide","offLabel":[],"synonyms":["amphotalide","amphothalide"],"timeline":[],"brandName":"Amphothalide","ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"Think of Amphothalide like a key that fits into a lock. The lock is a specific part of a cell, and the key is the Amphothalide molecule. When the key fits into the lock, it can change the way the cell works, which can help to treat a disease. However, the exact details of how Amphothalide works are still unclear.","oneSentence":"Amphothalide works by binding to a specific target, although the identity of this target is currently unknown.","technicalDetail":"Amphothalide's mechanism of action is not well understood, but it is believed to involve binding to a specific protein or receptor, potentially altering downstream signaling pathways."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3674","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AMPHOTALIDE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:43:13.912389","biosimilars":[],"competitors":[],"genericName":"amphotalide","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"95818EH730","CHEBI":"CHEBI:135382","INN_ID":"1079","UMLSCUI":"C0051759","ChEMBL_ID":"CHEMBL94192","PUBCHEM_CID":"71806","MESH_SUPPLEMENTAL_RECORD_UI":"C005616"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":1,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"1964 May-Jul","pmid":"14250531","title":"[STUDY OF THE ANTIBILHARZIC ACTION OF AMPHOTALIDE AS A FUNCTION OF THE DOSAGES EMPLOYED. RESULTS CONCERNING 25 CASES TREATED].","journal":"Bulletin de la Societe de pathologie exotique et de ses filiales"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amphothalide is a small molecule modality developed by an unknown entity, currently owned by an unknown entity. Its target and drug class are unknown, and it has not been approved by the FDA for any indications. The commercial status of Amphothalide is unclear, and it is not known whether it is patented or available as a generic. Further information on its pharmacokinetic properties, such as half-life and bioavailability, is also unavailable. As a result, key safety considerations and potential side effects are unknown.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}